Boston Scientific Counters J&J In “Perception Battle” With New Taxus Data
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific expects new clinical trial data presented at the Paris Course on Revascularization (PCR) May 24 to help reverse an ongoing shift of the drug-eluting stent market toward Johnson & Johnson/Cordis
You may also be interested in...
Medtronic Presents Durable Endeavor DES Results At ESC Meeting
Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial
Medtronic Presents Durable Endeavor DES Results At ESC Meeting
Medtronic's PMA for the Endeavor ABT-578-eluting stent will include data from over 2,800 patients, including three-year follow-up from the 100-patient ENDEAVOR-I trial
Boston Scientific Redraws U.S. Sales Map, Adds 25% More Taxus Reps
Boston Scientific plans to halt the decline of its U.S. drug-eluting stent market share by expanding its domestic interventional cardiology sales force by about 25% in the third quarter